• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Prednisone may have bone and cardiovascular benefits compared to hydrocortisone therapy in adrenal insufficiency

byAlex XiangandSimon Pan
April 3, 2026
in Chronic Disease, Endocrinology, Pharma
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Prednisolone therapy is well tolerated, may have better bone and cardiovascular outcomes compared to hydrocortisone, and poses lower medication burden compared to hydrocortisone therapy in adult patients with adrenal insufficiency (AI).

Evidence Rating Level: 1 (Excellent)

Study Rundown: Glucocorticoid replacement is an essential, lifesaving treatment of AI. Current standard management is 3 doses of hydrocortisone daily, with the largest dose upon waking to mimic the normal physiological cortisol circadian rhythm. However, even with appropriate therapy, patients with adrenal insufficiency have a shorter life expectancy by 12 years. This may be due to excess replacement, particularly later in the day, which is associated with increased bone loss, risk of cardiovascular deaths, and reduced quality of life. Prednisolone has a longer half-life and has been shown to give adequate glucocorticoid replacement while mimicking the circadian cortisol rhythm in a once-daily dose. No studies have compared the effects of once-daily prednisolone vs multiple daily doses of hydrocortisone on bone turnover.

This 2-arm, 2-period, double-blind, crossover randomized clinical trial was conducted in London, UK, from September 3, 2019, to December 14, 2023. Participants included adults aged 18-70 years with primary or secondary AI on stable glucocorticoid replacement therapy for the preceding 3 months. Participants were randomized 1:1 to receive prednisolone or hydrocortisone replacement therapy in the first 120-day study period, followed by the alternative treatment in the second 120-day study period. There was a minimum 2-week washout period. Corticosteroid dose was determined by the pretrial regimen already used by each participant.

Overall, this study found that prednisolone was associated with significantly slower bone turnover compared to hydrocortisone. Prednisolone was also significantly associated with greater reductions in weight, body mass index, and HbA1c. There were no significant differences in adverse events or subjective health outcomes.

Click here to read this study in JAMA Network Open

RELATED REPORTS

Lilly’s retatrutide achieves significant weight loss and A1C reduction in Phase 3 trial

Glucagon-like peptide-1 receptor agonists are associated with reduced risk of developing substance use disorders

Aerobic-resistance training and high-intensity interval training may improve metabolic and functional outcomes in adults with type 2 diabetes

Relevant reading: Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely Than Other Glucocorticoids

In-Depth [randomized clinical trial]:

Glucocorticoid replacement, an essential treatment of AI, is conventionally daily multiple-dose hydrocortisone. Clinical trials comparing this standard with once-daily prednisolone, which better mimics the physiological cycle of cortisol, are lacking. This randomized controlled trial compared metabolic outcomes in patients with AI receiving hydrocortisone vs. prednisolone. The primary outcome was bone turnover, measured by changes in multiple bone markers.

46 patients were randomized to receive prednisolone first (n = 24; median [IQR] age, 51.5 [42.8-63.2] years; 41.7% female) or hydrocortisone first (n = 22; median [IQR] age, 57.5 [48.2-62.0] years; 54.5% female). Compared with hydrocortisone, prednisolone was associated with significantly lower levels of multiple bone markers, including carboxylated osteocalcin (−1.22 ng/mL; 95% CI, −2.35 to −0.10 ng/mL; P = .04), undercarboxylated osteocalcin (−1.38 ng/mL; 95% CI, −2.32 to −0.44 ng/mL; P = .005), urinary N-terminal telopeptide (−9.34 nmol/mmol; 95% CI, −15.40 to −3.29 nmol/mmol; P = .002), and procollagen type 1 N-terminal propeptide (−13.80 ng/mL; 95% CI, −22.20 to −5.49 ng/mL; P < .001). Prednisolone was also associated with significantly greater reductions in weight (−1.87 kg; 95% CI, −3.02 to −0.72 kg; P = .002) and HbA1c (−0.12% [−1.23 mmol/mol; 95% CI, −1.95 to −0.51 mmol/mol]; P = .001). There were no significant differences in fasting glucose, insulin, lipids, or blood pressure. There were also no significant differences in subjective health outcomes, as measured by the Addison’s Disease-Specific Quality of Life Questionnaire, or in the incidence of adverse events.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adrenal insufficiencycardiovascular eventsendocrinologyhydrocortisoneprednisone
Previous Post

Lilly’s retatrutide achieves significant weight loss and A1C reduction in Phase 3 trial

RelatedReports

Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Lilly’s retatrutide achieves significant weight loss and A1C reduction in Phase 3 trial

April 3, 2026
Chronic Disease

Glucagon-like peptide-1 receptor agonists are associated with reduced risk of developing substance use disorders

March 9, 2026
Pediatric DKA associated with recent acute care visits
Chronic Disease

Aerobic-resistance training and high-intensity interval training may improve metabolic and functional outcomes in adults with type 2 diabetes

January 13, 2026
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Cardiology

Steroidal mineralocorticoid receptor antagonists show little mortality benefit in patients receiving dialysis

September 18, 2025

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Prednisone may have bone and cardiovascular benefits compared to hydrocortisone therapy in adrenal insufficiency
  • Lilly’s retatrutide achieves significant weight loss and A1C reduction in Phase 3 trial
  • Early surgical valve replacement offers survival benefit in asymptomatic, very severe aortic stenosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

The Classics in Medicine Paperback Released!

Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.

amazon-logo_blackGet-it-on-iBooks-badge

Click anywhere to close this announcement

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.